<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126449</url>
  </required_header>
  <id_info>
    <org_study_id>NL44684.058.13</org_study_id>
    <secondary_id>BOOG2013-04</secondary_id>
    <secondary_id>p13.135</secondary_id>
    <nct_id>NCT02126449</nct_id>
  </id_info>
  <brief_title>DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer</brief_title>
  <acronym>DIRECT</acronym>
  <official_title>DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Borstkanker Onderzoek Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pink Ribbon Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preclinical studies provide strong support for the concept that fasting evokes resistance to
      multiple forms of stress. Fasting reduces plasma levels of growth factors and modulates
      intracellular nutrient sensing systems, thereby diverting energy from growth to maintenance.
      Accordingly, the currently available preclinical evidence suggests that short-term fasting
      protects normal cells against the perils of chemotherapy. In contrast, cancer cells are not
      protected, as a result of their self-sufficiency in growth signals. This phenomenon is termed
      Differential Stress Resistance (DSR). DSR reduces the severity of toxic side-effects of
      chemotherapy and interestingly, it simultaneously renders cancer cells more vulnerable to
      chemotherapeutics. Importantly, extensive preclinical evidence and preliminary clinical data
      indicate that a specifically designed very low calorie, low amino acid substitution diet
      (&quot;Fasting Mimicking Diet, FMD&quot;) has effects on cancer therapy that are very similar to those
      of fasting. This study aims to evaluate the impact of the FMD on tolerance to and efficacy of
      neoadjuvant chemotherapy in women with stage II or III breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients with grade III/IV toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version (NCI CTCAE) v4.03.</measure>
    <time_frame>2 years</time_frame>
    <description>Phase II</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of pCR.</measure>
    <time_frame>4 years</time_frame>
    <description>Phase III</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response measured by MRI (RECIST1.1) after 4 cycles chemotherapy.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade I/II side effects of chemotherapy according to NCI CTCAE v4.03.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic (Glucose, insulin, insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein 3 (IGF-BP3), free thyroxin (FT4), triiodothyronine (T3) and thyroid-stimulating hormone (TSH)) and inflammatory response (CRP) to chemotherapy.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA damage, apoptosis, immunology and nutrient sensing system activity in the tumor.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's quality of life (using EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires), burden of therapy noted by a visual analogue scale (VAS) (Distress Thermometer) and differences of Illness Perceptions (B-IPQ).</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term efficacy of treatment (DFS, OS).</measure>
    <time_frame>4years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone receptor percentage, Ki67 and immunologic tumor profile and tumor/stroma ratio as predictive biomarker</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SNPs used as biomarker to predict treatment outcome.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Protein profiles and cytokines used as biomarker to predict treatment outcome</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quantification of chemotherapy-induced DNA damage in leukocytes (with γ-H2AX modification and comet assay).</measure>
    <time_frame>3years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quantification of nutrient sensing system gene expression (with western blot).</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Fasting Mimicking Diet</condition>
  <condition>Breast Cancer</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <condition>Pathological Complete Response</condition>
  <arm_group>
    <arm_group_label>Fasting mimicking diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short term fasting using Fasting mimicking diet around neoadjuvant chemotherapy (AC&gt;T)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>regular diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard neoadjuvant chemotherapy (AC&gt;T)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fasting mimicking diet</intervention_name>
    <arm_group_label>Fasting mimicking diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with stage II or III (cT1cN+ or ≥T2 any cN, cM0) breast cancer
             receiving neoadjuvant AC-T

          -  Measurable disease (breast and/or lymph nodes)

          -  HER2 negative core biopsy Age ≥18 years

          -  WHO performance status 0-2

          -  Adequate bone marrow function : white blood cells (WBCs) ≥3.0 x 109/l, neutrophils
             ≥1.5 x 109/l, platelets ≥100 x 109/l

          -  Adequate liver function: bilirubin ≤1.5 x upper limit of normal (UNL) range, ALAT
             and/or ASAT ≤2.5 x UNL, Alkaline Phosphatase ≤5 x UNL

          -  Adequate renal function: the calculated creatinine clearance should be ≥50 mL/min

          -  Patients must be accessible for treatment and follow-up

          -  Written informed consent according to the local Ethics Committee requirements

          -  Willing to fill in quality of life questionnaires

          -  Able to read and write in Dutch

        Exclusion Criteria:

          -  History of breast cancer (invasive or non-invasive)

          -  Previous malignancy within 5 years, with exception of a history of a previous basal
             cell carcinoma of the skin or pre-invasive carcinoma of the cervix.

          -  Serious other diseases such as recent myocardial infarction, clinical signs of cardiac
             failure or clinically significant arrhythmias

          -  Diabetes Mellitus

          -  Body mass index (BMI) &lt; 19 kg/m2

          -  Pregnancy or lactating

          -  Significant food allergies which would make the subject unable to consume the food
             provided (ex: nuts or soy)

          -  Any metabolic disorders that may affect gluconeogenesis or adaptation to short fasting
             periods.

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the patient to complete the study or sign meaningful informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith R Kroep, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanno Pijl, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Koos JM van der Hoeven, MD PhD Ir</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith R Kroep, MD, PhD</last_name>
    <phone>+31715263464</phone>
    <email>j.r.kroep@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefanie de Groot, MD</last_name>
    <phone>+31715263464</phone>
    <email>s.de_groot2@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-holland</state>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith R Kroep, MD, PhD</last_name>
      <phone>+31715263464</phone>
      <email>j.r.kroep@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Stefanie de Groot, MD</last_name>
      <phone>+31715263464</phone>
      <email>s.de_groot2@lumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>J R Kroep, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>H Pijl, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>J JM van der Hoeven, Md PhD Ir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M P Hendriks, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J M Meerum Terwogt, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alexander Monro hospital</name>
      <address>
        <city>Bilthoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E. Goker , MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J B Heijns, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deventer Hospital</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A LT Imholz, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>L W Kessels, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Valei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Baars, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>, Catharina ziekenhuis Hospital</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B EPJ Vriens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kennemer gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>G.J. Klerk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H de Graaf, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bronovo Hospital</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N I Weijl, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haga Hospital</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Portielje, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VieCurie Hospital</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Y van de Wouw, Md PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lange Land Hospital</name>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A JM Pas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A H Honkoop, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.boogstudycenter.nl</url>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>December 30, 2017</last_update_submitted>
  <last_update_submitted_qc>December 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>J.R. Kroep</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

